Key result
Undertreatment of dyslipidemia universally reduces the efficacy of hypolipidemic drugs in lowering cardiovascular event rates.
Key points are not available for this paper at this time.
Design
Editorial
Undertreatment of dyslipidemia remains a global issue that blunts the potential cardiovascular benefits of lipid-lowering therapies.
Undertreatment of dyslipideamia is a universal problem and reduces the efficasy of hypolipidaemic drugs to reduce cardiovascular event rates. The means to face this problem are available and should be utilized to optimize dyslipidaemia control and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Athyros et al. (2014) studied this question. Undertreatment of dyslipidemia universally reduces the efficacy of hypolipidemic drugs in lowering cardiovascular event rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: